FDA accepts NDA for tesamorelin for HIV lipodystrophy
This article was originally published in Scrip
Executive Summary
The US FDA has accepted an NDA for Theratechnologies' lead drug candidate, tesamorelin, for the treatment of excess abdominal fat in HIV patients with lipodystrophy. This development triggered a $10 million payment from EMD Serono, an affiliate of Merck KGaA, which has licensed commercialisation rights for the drug in the US.